compounded tirzepatide efficacy $125/mo (vs $1,069 Mounjaro) Compounded Tirzepatide (GLP-1/GIP)

2-4 lb weight loss Months 2-3: Noticeable weight loss (5-8%)

Since it led to over 20% weight loss in the SURMOUNT-1 trial, it was approved for weight loss by the FDA in the United States in November 2023 (as Zepbound) and will hopefully be approved by Health Canada in the near future

Solution leakage (medication dripping from the injection site)

Next came tirzepatide (Zepbound and Mounjaro), which acts on GLP-1 as well as GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone

Body weight also improved significantly in all groups

For more information on Google Analytics cookies, see the official Google Analytics page